An interventional study of Exercise in Systemic Lupus Erythematosus, sponsored by University Medical Center Mainz. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-11-10.
Sponsored by University Medical Center Mainz · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Lupus Erythematosus, Systemic with a site in Germany — 26 open to participants now, 47 under way, 19 of them phase 3. Lupus Erythematosus, Systemic · Germany.
Among the 125 studies in Lupus Erythematosus, Systemic with a site in Germany, this one is the 95th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2018, is one of 3 with no phase, and was the 56th registered.
1,211 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →26 of the 125 studies in Lupus Erythematosus, Systemic with a site in Germany are open now. Recruiting first, the newest first:
Diabetes Free, Inc. · Sites in Germany
Ages 18+
AstraZeneca · Sites in Germany, United States, Argentina and 32 more countries
Ages 5–80
Boehringer Ingelheim · Sites in Germany, United States, Argentina and 18 more countries
Ages 18–74
AstraZeneca · Sites in Germany, United States, Canada and 6 more countries
Ages 18–70
EMD Serono Research & Development Institute, Inc. · Sites in Germany, United States, Australia and 17 more countries
Ages 18–75
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 94 (33%) set no upper age limit and 160 (56%) stop at 75 or younger; 54 take children under 18; 32 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 46 · Phase 3 46 · Phase 4 1
First in 2004; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 52 across 879 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 224 across the 112 interventional studies, 125 across the 13 observational. Of the 71 that completed or were terminated, 44 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
114 of 125 have an industry lead sponsor. The 10 most frequent:
University Medical Center Mainz is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
University Medical Center Mainz has 1 study filed under Lupus Erythematosus, Systemic — fewer than ten, so there is no comparison to draw.
12 of the studies in Lupus Erythematosus, Systemic with a site in Germany that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05138133Phase 3AstraZenecaPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | 2027-02-23 |
| NCT05843643Phase 3AbbVieProgram to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | 2027-03 |
| NCT05624749Phase 3Novartis PharmaceuticalsPhase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) | 2027-04-12 |
| NCT05126277Phase 3Novartis PharmaceuticalsSafety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | 2027-09-21 |
Add all 12 to your calendar (.ics) → With an account.
Among the 125 studies in Lupus Erythematosus, Systemic with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This pilot study is a randomized controlled trial to assess the effect of an individualized supervised exercise program in patients with systemic lupus erythematosus (SLE) compared to treatment-as-usual (TAU).
The aim of this study is to evaluate the effect of a 12-week individualized exercise program in subjects with SLE in comparison to treatment-as-usual therapy. Several previous studies showed that exercise leads to various benefits in treating SLE, including enhanced aerobic capacity, reduced symptoms of depression and fatigue. Moreover, it has been shown that exercise is well tolerated and does not impair disease activity in SLE negatively. Here, the effects of an individual internet-based exercise therapy for 12 weeks will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will obtain no exercise program. After 12 weeks, the patients in the control group will be invited to participate in the training group.
Participants will obtain aerobic exercise only.
Other: Exercise
Participants will obtain aerobic and anaerobic exercise respectively
Other: Exercise
Participants will obtain an individualized exercise program based on entrance examination on treadmill.
Peak oxygen uptake (VO2peak)
Change of VO2peak after 12-weeks compared to baseline.
Time frame: 12-weeks
Fatigue Scale for Motor and Cognitive Functions (FSMC)
Change of FSMC score after 12-weeks compared to baseline. The FSMC consists of 20 items (five-point Likert scale, from "absolutely agree" to "absolutely disagree") to assess cognitive fatigue (10 items) and motor fatigue (10 items). The summed scores for cognitive and motor fatigue result in the sum score. A cut-off value of 43 indicates mild fatigue, whereas higher values are associated with moderate fatigue (≥53) or severe fatigue (≥63).
Time frame: 12-weeks
Beck Depression Inventar (BDI)
Change of BDI score after 12-weeks compared to baseline to measure the severity of depression. The BDI questionnaire consists of 21 sets of statements. Each set consists of 4 statements which are ranked in terms of severity from 0 to 3. The sum of the item scores (range 0-63) indicates the severity of depression. The standardized scale is: 0-8: no depression. 9-13: minimal depression. 14-19: mild depression. 20-28: moderate depression. 29-63: severe depression.
Time frame: 12-weeks
Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)
The Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA) - Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (SELENA-SLEDAI) will be used to measure the disease activity. The index consist of 24 items including clinical and laboratory variables to measure disease activity within the previous 10 days. The maximum score is 105. SLEDAI scores \>3 indicate a mild or moderate flare, SLEDAI ≥12 indicate a severe flare.
Time frame: 12-weeks
Disease Activity Score 28 (DAS 28)
Change of DAS 28 score after 12-weeks compared to baseline. The DAS 28 score indicates rheumatoid arthritis disease activity and treatment response. The score composes of 4 measures including the number of swollen/tender joints, C reactive protein and patients health assessment. A total score is calculated using the DAS 28 formula. Values range from 2.0 to 10, whereas higher values indicate higher disease activity.
Time frame: 12-weeks
Work Ability Index (WAI)
The WAI self-assessment questionnaire will be used to assess the workability of the patients. The questionnaire covers six dimensions including current workability, as well as past 2 year estimation among others. The answers have different scores, which are summed to a total score, leading to four categories. 7-27 points indicate bad, 28-36 points moderate, 37-43 good, and 44-49 points very good workability.
Time frame: 12-weeks
Circulating, cell-free Deoxyribonucleic acid (CfDNA)
The concentration of cfDNA (ng/ml) will be measured during and after acute exercise at baseline and after 12-weeks exercise intervention using quantitative PCR. Compared to healthy subjects SLE patients show higher cfDNA plasma levels.
Time frame: 12-weeks
Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI)
Change of score on RCLASI after 12-weeks compared to baseline. The RCLASI scoring system includes the RCLASI Activity Score to measure the activity of skin lesions, and the RCLASE Damage Score to measure the damage of skin lesions in patients with discoid lupus erythematosus and cutaneous lupus erythematosus. The score is used as a follow-up parameter for the Lupus activity of the skin. It was also shown that RCLASI correlates well with the physicians and patients global assessment of disease activity.
Time frame: 12-weeks
Extra cellular vesicles (EVs)
The relative amount of EV subpopulations will be analyzed before and after acute exercise, as well as after 12-weeks of exercise intervention using bead isolation and or size exclusion chromatography followed by protein marker characterization.
Time frame: 12-weeks
Autoantibodies
Change of antinuclear antibodies (ANA) titer after 12-weeks of exercise intervention compared to baseline (standard value ≤1:80).
Time frame: 12-weeks
Ventilatory threshold (VT)
Change of VT after 12-weeks compared to baseline.
Time frame: 12-weeks
Muscle mass
Change of muscle mass after 12-weeks compared to baseline. Muscle mass will be measured in absolute mass \[kg\] including internal organs using bioelectrical impedance analysis (InBody 3.0 Body composition analyzer).
Time frame: 12-weeks
Chair-Stand-Test (CST)
Change of CST after 12-weeks compared to baseline.
Time frame: 12-weeks
Ran from Mar 2018 to primary completion in Apr 2020, 25 months.
Of 123 non-industry interventional studies with no phase under Lupus Erythematosus, Systemic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's 25 months is close to that.
Counting every sponsor, half of 130 studies reached it within 23 months; a quarter within 10 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Lupus Erythematosus, Systemic →
University Medical Center Mainz